Prognostic Value of Plasma hPG$_{80}$ (Circulating Progastrin) in Metastatic Renal Cell Carcinoma

Manish Kohli, Winston Tan, Bérengère Vire, Pierre Liaud, Mélina Blairvacq, Frederic Berthier, Daniel Rouison, George Garnier, Léa Payen, Thierry Cousin, Dominique Joubert, Alexandre Prieur

**Figure S1.** Flowchart of the study with RCC patients.

Figure S2. Levels and performances of plasma hPG$_{80}$ in patients with RCC patients. A. hPG$_{80}$ concentrations in RCC patients ($n = 39$) compared to 18-25 ($n = 137$) and 50-80 ($n = 252$) years old control groups. One-tailed Mann-Whitney test. B to C. Diagnostic discriminative accuracies of hPG$_{80}$ in RCC patients compared to control groups aged 18-25 year old (B) or 50-80 year old (C) using Receiver Operating Characteristics (ROC) curve analysis.

Table S1. Clinical and pathological characteristics for RCC patients.

		RCC
		N (%)
		$n = 39$
Age, years	Median (range)	67 (25–83)
Gender	Male	25 (64.1%)
	Female	14 (35.9%)
Histology	Clear cell	21
	Chromophobe	3
	Papillary	10
	Other	5
Fuhrman Grade (G)	G1	2
	G2	15
	G3	7
	G4	9
	Not applicable	5

	Unspecified	1
Sarcomatoid differentiation	Present	NA
	Absent	NA
Necrosis	Present	NA
	Absent	NA
Clinical stage	I	23
	II	4
	III	11
	IV	0
	Unspecified	1

NA: non available

Table S2. hPG_{80} levels in RCC patients.

		N	hPG80	
			Median (IQR), pM	Mean (SE), pM
Patients	RCC	39	7.36 (3.05-18.23)	10.73 (1.61)